Refine
Has Fulltext
- yes (77)
Is part of the Bibliography
- yes (77)
Year of publication
Document Type
- Journal article (68)
- Doctoral Thesis (8)
- Other (1)
Language
- English (77) (remove)
Keywords
- ADHD (11)
- children (8)
- adolescents (5)
- adolescence (4)
- methylphenidate (4)
- NSSI (3)
- RCT (3)
- brain (3)
- brain development (3)
- eating disorders (3)
- fear generalization (3)
- mental health (3)
- Early-onset (2)
- GAD1 (2)
- Jugend (2)
- Kind (2)
- PARK2 (2)
- Parkinson’s disease (2)
- Tourette syndrome (2)
- anorexia nervosa (2)
- attention deficit/hyperactivity disorder (2)
- attention-deficit/hyperactivity disorder (ADHD) (2)
- biomarkers (2)
- brain disorders (2)
- case report (2)
- dopamine (2)
- emotion regulation (2)
- fMRI (2)
- fear conditioning (2)
- hiPSC (2)
- nervous system (2)
- norepinephrine (2)
- outcome (2)
- pharmacovigilance (2)
- prosocial behavior (2)
- proteomics (2)
- psychiatric disorders (2)
- serum concentration (2)
- substantia nigra pars compacta (2)
- therapeutic drug monitoring (2)
- working memory (2)
- 1p36 deletion syndrome (1)
- 21q22.2-q22.3 (1)
- 22q11.2 deletion syndrome (1)
- AKI (1)
- Adolescence (1)
- Altersunterschied (1)
- Angst (1)
- Angst als Eigenschaft (1)
- Angsterkrankungen (1)
- Animal model (1)
- Anorexia nervosa (1)
- Attention-deficit/hyperactivity disorder (1)
- Aufmerksamkeits-Defizit-Syndrom (1)
- Aufmerksamkeitsdefizit-Syndrom (1)
- Aversive tension (1)
- BDNF (1)
- BMI (1)
- Big Five (1)
- Biomarkers (1)
- Braak (1)
- CDH13 (1)
- CNS imaging (1)
- CNV (1)
- CNVs (1)
- COMT (1)
- COVID-19 (1)
- Central nervous system (1)
- Childhood (1)
- Children (1)
- Clinical Genetics (1)
- Comorbidity survey replication (1)
- DBT (1)
- DSM-IV disorders (1)
- De-novo (1)
- Disease progression (1)
- Disease-modifying therapies (1)
- Distress (1)
- Dopamine (1)
- Drug development (1)
- ESCAlife (1)
- Eating disorder (1)
- Ecological momentary assessment (1)
- Emotion regulation (1)
- Enrichment analysis (1)
- Erratum (1)
- FOXP2 (1)
- Fgf-signalling (1)
- Fibromyalgia (1)
- Follow-up (1)
- Furcht (1)
- Furchtkonditionierung (1)
- GABA (1)
- GFAP (1)
- GRM8 (1)
- GWAS (1)
- Genetic etiology (1)
- Hurst Exponent (1)
- Hyperactivity (1)
- Hypothalamus (1)
- Impulsivität (1)
- Jugendliche (1)
- KDIGO (1)
- Kinder (1)
- Kindheit und Jugend (1)
- Kleinkern (1)
- Konditionierung (1)
- Lebenslauf (1)
- Locomotor activity (1)
- Medical students (1)
- Medicine (1)
- Metaanalyse (1)
- Metaanalysis (1)
- Methylphenidat (1)
- Mindfulness (1)
- Neuroprotection (1)
- OCD (1)
- Parent–Child Interaction Therapy (PCIT) (1)
- Parkinson (1)
- Parkinson's disease (1)
- Prevalence (1)
- Prävention (1)
- STBS (1)
- Scale (1)
- Serotonin (1)
- Smartphones (1)
- Stress (1)
- Stress prevention (1)
- Substantia nigra (1)
- Surrogate endpoints (1)
- TCS (1)
- TIC disorder (1)
- TIC disorders (1)
- Therapy (1)
- Thigmotaxis (1)
- Transkranielle Sonographie (1)
- VAL66MET polymorphism (1)
- VBM (1)
- Verhaltenstherapie (1)
- Waiting Impulsivity (1)
- Zebrafish (1)
- actigraphy (1)
- adolescence anorexia nervosa (1)
- adult attention deficit/hyperactivity disorder (1)
- adult development (1)
- adult neurogenesis (1)
- adult treatment (1)
- adverse effects (1)
- adversity (1)
- affective disorders (1)
- agreeableness (1)
- allostatic load (1)
- amenorrhea (1)
- analgesic medication (1)
- anticipatory mechanisms (1)
- artifacts (1)
- association (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attention-deficit/hyperactivity disorder (1)
- auditory discrimination (1)
- autism (1)
- autoantibodies (1)
- basal ganglia (1)
- behavior problems (1)
- behaviour therapy (1)
- biomarker (1)
- bipolar disorder (1)
- body mass index (1)
- bone-mineral density (1)
- breastfeeding (1)
- cancer (1)
- cardiac surgery (1)
- catecholamines (1)
- caudate nucleus (1)
- challenging behaviours (1)
- child behavior (1)
- child memory (1)
- childhood maltreatment (1)
- children/adults (1)
- chromosome 21 (1)
- chronotype (1)
- classical conditioning (1)
- classification (1)
- clinical characteristics (1)
- clinical trial (1)
- coercive measures (1)
- common SNPS (1)
- comparative genomics (1)
- complex diseases (1)
- computational modeling (1)
- congenital heart-deffects (1)
- contingent negative-variation (1)
- continuous performance task (CPT) (1)
- continuous performance-test (1)
- coping strategies (1)
- copy-number variation (1)
- correlate (1)
- cytogenetic effects (1)
- data quality (1)
- deficit hyperactivity disorder (1)
- deficit-hyperactivity disorder (1)
- dementia with Lewy bodies (1)
- depression (1)
- depressive symptoms (1)
- depressiveness (1)
- development (1)
- developmental disabilities (1)
- developmental dyscalculia (1)
- developmental dyslexia (1)
- digital phenotyping (1)
- disability (1)
- discrimination training (1)
- disease modelling (1)
- disease progression (1)
- disease-modifying therapies (1)
- disorders (1)
- distal deletion (1)
- dopamine transporter (DAT) (1)
- dopaminergics (1)
- doublecortine-like (1)
- drug development (1)
- drug safety (1)
- dual guidance (1)
- dyscalculia (1)
- dyslexia (1)
- ecological momentary assessment (1)
- efficacy (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- emotional dysregulation (1)
- employee stress (1)
- endophenotype (1)
- event-related potentials (1)
- excitatory/inhibitory imbalance (1)
- executive functions (1)
- expression (1)
- family (1)
- family relations (1)
- fear extinction (1)
- fear-relevant training (1)
- feedback (1)
- fibromyalgia syndrome (1)
- frontal cortex (1)
- functional magnetic resonance imaging (1)
- genes (1)
- genome-wide association (1)
- genomic imaging (1)
- gilles (1)
- girls (1)
- glucose transporter (1)
- guidelines & recommendations (1)
- haplotypes (1)
- hierarchical modeling (1)
- hippocampus (1)
- iPSC (1)
- identification (1)
- impulse control disorders (1)
- inattention/hyperactivity (1)
- increases (1)
- individualised modular treatment programme (1)
- intellectual disabilities (1)
- intelligence (1)
- intra-individual variability (IIV) (1)
- inventory (1)
- kinase (1)
- longitudinal studies (1)
- longitudinal study (1)
- maternal stress (1)
- mathematics (1)
- maturation (1)
- melatonin (1)
- menarche (1)
- menstrual recovery (1)
- mental disorders (1)
- meta-analysis (1)
- metabotropic glutamate (mGlu) receptor (1)
- micronucleus assay (1)
- mindfulness (1)
- minimum reporting standards (1)
- mismatch (1)
- mismatch negativity mmn (1)
- missing heritability (1)
- mitochondria (1)
- mitochondrial pathology (1)
- mitochondrial translation (1)
- mobile crowdsensing (1)
- mobile health (1)
- molecular neuroscience (1)
- moral balancing (1)
- mothers (1)
- motor preparation (1)
- multicenter study (1)
- multi‑center cohort study (1)
- mutagenicity (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurogenesis (1)
- neuromelanin granules (1)
- neuroprotection (1)
- neuropsychiatric disorders (1)
- nonsuicidal self-injury (NSSI) (1)
- noradrenaline (1)
- novelty detection (1)
- nucleus accumbens (1)
- objective assessment (1)
- off label use (1)
- older adults (1)
- olfactory bulb neurogenesis (1)
- oppositional defiant disorder (1)
- oppositional-defiant disorder (1)
- ovarian function (1)
- paediatrics (1)
- parent training (1)
- parent-child interaction therapy (PCIT) (1)
- parent-child relationship (1)
- parental perception (1)
- parents (1)
- peripheral nerve involvement (1)
- pharmacokinetics (1)
- precursor symptoms (1)
- prelevance (1)
- preterm children (1)
- prevalence (1)
- prevention (1)
- probabilistic reversal learning (1)
- probiotic prophylaxis (1)
- processing deficits (1)
- prosocial (1)
- prosociality (1)
- protective factors (1)
- psychopathology (1)
- psychosis (1)
- psychotropic drugs (1)
- quantitative trait (1)
- rare diseases (1)
- reaction time (1)
- reading disability (1)
- recovery (1)
- reinforcement learning (1)
- reliability (1)
- research errors (1)
- residential institutions (1)
- resilience (1)
- responsivity (1)
- resumption of menses (1)
- return (1)
- review (1)
- risperidone (1)
- satisfaction with life (1)
- schizophrenia (1)
- school (1)
- school-based prevention (1)
- schoolchildren (1)
- selective mutism (1)
- self-injury (1)
- self-regulation (1)
- selfcompassion (1)
- short-term methylphenidate brain (1)
- single photon emission computed tomography (SPECT) (1)
- skin conductance (1)
- sleep (1)
- slow cortical potentials (1)
- social influence (1)
- social recognition (1)
- speech perception (1)
- stem cells (1)
- strength and difficulties (1)
- stress (1)
- stress granules (1)
- stress reduction (1)
- stressful life events (1)
- striatum (1)
- study (1)
- subventricular zone (1)
- suicidality (1)
- sulcal morphology (1)
- supplements (1)
- support vector machines (1)
- surrogate endpoints (1)
- susceptibility gene (1)
- synaptosomes (1)
- syndrome (1)
- target weight (1)
- telephone-assisted self-help (1)
- tetrahydroisoquinoline derivates (1)
- third-wave psychotherapy (1)
- tics (1)
- transcranial sonography (1)
- transcutaneous auricular vagus nerve stimulation (1)
- transcutaneous cervical vagus nerve stimulation (1)
- transcutaneous vagus nerve stimulation (1)
- transporter gene SLC2A3 (1)
- tumor-suppressor gene (1)
- universal prevention (1)
- ventricular zone (1)
- vitamin D (1)
- weight gain (1)
Institute
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (77) (remove)
Sonstige beteiligte Institutionen
Fractal phenomena can be found in numerous scientific areas including neuroscience. Fractals are structures, in which the whole has the same shape as its parts. A specific structure known as pink noise (also called fractal or 1/f noise) is one key fractal manifestation, exhibits both stability and adaptability, and can be addressed via the Hurst exponent (H). FMRI studies using H on regional fMRI time courses used fractality as an important characteristic to unravel neural networks from artificial noise. In this fMRI-study, we examined 103 healthy male students at rest and while performing the 5-choice serial reaction time task. We addressed fractality in a network associated with waiting impulsivity using the adaptive fractal analysis (AFA) approach to determine H. We revealed the fractal nature of the impulsivity network. Furthermore, fractality was influenced by individual impulsivity in terms of decreasing fractality with higher impulsivity in regions of top-down control (left middle frontal gyrus) as well as reward processing (nucleus accumbens and anterior cingulate cortex). We conclude that fractality as determined via H is a promising marker to quantify deviations in network functions at an early stage and, thus, to be able to inform preventive interventions before the manifestation of a disorder.
There is no approved drug for fibromyalgia syndrome (FMS) in Europe. In the German S3 guideline, amitriptyline, duloxetine, and pregabalin are recommended for temporary use. The aim of this study was to cross-sectionally investigate the current practice of medication in FMS patients in Germany. We systematically interviewed 156 patients with FMS, while they were participating in a larger study. The patients had been stratified into subgroups with and without a decrease in intraepidermal nerve fiber density. The drugs most commonly used to treat FMS pain were nonsteroidal anti-inflammatory drugs (NSAIDs) (41.0% of all patients), metamizole (22.4%), and amitriptyline (12.8%). The most frequent analgesic treatment regimen was “on demand” (53.9%), during pain attacks, while 35.1% of the drugs were administered daily and the remaining in other regimens. Median pain relief as self-rated by the patients on a numerical rating scale (0–10) was 2 points for NSAIDS, 2 for metamizole, and 1 for amitriptyline. Drugs that were discontinued due to lack of efficacy rather than side effects were acetaminophen, flupirtine, and selective serotonin reuptake inhibitors. Reduction in pain severity was best achieved by NSAIDs and metamizole. Our hypothesis that a decrease in intraepidermal nerve fiber density might represent a neuropathic subtype of FMS, which would be associated with better effectiveness of drugs targeting neuropathic pain, could not be confirmed in this cohort. Many FMS patients take “on-demand” medication that is not in line with current guidelines. More randomized clinical trials are needed to assess drug effects in FMS subgroups.
CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement
(2022)
We tested the hypothesis that reduced skin innervation in fibromyalgia syndrome is associated with specific CNS changes. This prospective case–control study included 43 women diagnosed with fibromyalgia syndrome and 40 healthy controls. We further compared the fibromyalgia subgroups with reduced (n = 21) and normal (n = 22) skin innervation. Brains were analysed for cortical volume, for white matter integrity, and for functional connectivity. Compared to controls, cortical thickness was decreased in regions of the frontal, temporal and parietal cortex in the fibromyalgia group as a whole, and decreased in the bilateral pericalcarine cortices in the fibromyalgia subgroup with reduced skin innervation. Diffusion tensor imaging revealed a significant increase in fractional anisotropy in the corona radiata, the corpus callosum, cingulum and fornix in patients with fibromyalgia compared to healthy controls and decreased FA in parts of the internal capsule and thalamic radiation in the subgroup with reduced skin innervation. Using resting-state fMRI, the fibromyalgia group as a whole showed functional hypoconnectivity between the right midfrontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. The subgroup with reduced skin innervation showed hyperconnectivity between the inferior frontal gyrus, the angular gyrus and the posterior parietal gyrus. Our results suggest that the subgroup of fibromyalgia patients with pronounced pathology in the peripheral nervous system shows alterations in morphology, structural and functional connectivity also at the level of the encephalon. We propose considering these subgroups when conducting clinical trials.
Background:
Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning.
Methods
Thirteen adolescent male patients (9–16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH.
Results
On-MPH status was associated with a highly significant change (−29.9%) of striatal DAT BP as compared to off-MPH (t = −4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04).
Conclusion
Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.
Physical and mental well-being during the COVID-19 pandemic is typically assessed via surveys, which might make it difficult to conduct longitudinal studies and might lead to data suffering from recall bias. Ecological momentary assessment (EMA) driven smartphone apps can help alleviate such issues, allowing for in situ recordings. Implementing such an app is not trivial, necessitates strict regulatory and legal requirements, and requires short development cycles to appropriately react to abrupt changes in the pandemic. Based on an existing app framework, we developed Corona Health, an app that serves as a platform for deploying questionnaire-based studies in combination with recordings of mobile sensors. In this paper, we present the technical details of Corona Health and provide first insights into the collected data. Through collaborative efforts from experts from public health, medicine, psychology, and computer science, we released Corona Health publicly on Google Play and the Apple App Store (in July 2020) in eight languages and attracted 7290 installations so far. Currently, five studies related to physical and mental well-being are deployed and 17,241 questionnaires have been filled out. Corona Health proves to be a viable tool for conducting research related to the COVID-19 pandemic and can serve as a blueprint for future EMA-based studies. The data we collected will substantially improve our knowledge on mental and physical health states, traits and trajectories as well as its risk and protective factors over the course of the COVID-19 pandemic and its diverse prevention measures.
Background: Hyperactivity is one of the core symptoms in attention deficit hyperactivity disorder (ADHD). However, it remains unclear in which way the motor system itself and its development are affected by the disorder. Movement-related potentials (MRP) can separate different stages of movement execution, from the programming of a movement to motor post-processing and memory traces. Pre-movement MRP are absent or positive during early childhood and display a developmental increase of negativity.
Methods: We examined the influences of response-speed, an indicator of the level of attention, and stimulant medication on lateralized MRP in 16 children with combined type ADHD compared to 20 matched healthy controls.
Results: We detected a significantly diminished lateralisation of MRP over the pre-motor and primary motor cortex during movement execution (initial motor potential peak, iMP) in patients with ADHD. Fast reactions (indicating increased visuo-motor attention) led to increased lateralized negativity during movement execution only in healthy controls, while in children with ADHD faster reaction times were associated with more positive amplitudes. Even though stimulant medication had some effect on attenuating group differences in lateralized MRP, this effect was insufficient to normalize lateralized iMP amplitudes.
Conclusions: A reduced focal (lateralized) motor cortex activation during the command to muscle contraction points towards an immature motor system and a maturation delay of the (pre-) motor cortex in children with ADHD. A delayed maturation of the neuronal circuitry, which involves primary motor cortex, may contribute to ADHD pathophysiology.
Recent studies as well as theoretical models of error processing assign fundamental importance to the brain's dopaminergic system. Research about how the electrophysiological correlates of error processing—the error-related negativity (ERN) and the error positivity (Pe)—are influenced by variations of common dopaminergic genes, however, is still relatively scarce. In the present study, we therefore investigated whether polymorphisms in the DAT1 gene and in the DRD4 gene, respectively, lead to interindividual differences in these error processing correlates. One hundred sixty participants completed a version of the Eriksen Flanker Task while a 26-channel EEG was recorded. The task was slightly modified in order to increase error rates. During data analysis, participants were split into two groups depending on their DAT1 and their DRD4 genotypes, respectively. ERN and Pe amplitudes after correct responses and after errors as well as difference amplitudes between errors and correct responses were analyzed. We found a differential effect of DAT1 genotype on the Pe difference amplitude but not on the ERN difference amplitude, while the reverse was true for DRD4 genotype. These findings are in line with predictions from theoretical models of dopaminergic transmission in the brain. They furthermore tie results from clinical investigations of disorders impacting on the dopamine system to genetic variations known to be at-risk genotypes.
Background:
Attention deficit/hyperactivity disorder has been shown to affect working memory, and fMRI studies in children and adolescents with attention deficit/hyperactivity disorder report hypoactivation in task-related attentional networks. However, studies with adult attention deficit/hyperactivity disorder patients addressing this issue as well as the effects of clinically valid methylphenidate treatment are scarce. This study contributes to closing this gap.
Methods:
Thirty-five adult patients were randomized to 6 weeks of double-blind placebo or methylphenidate treatment. Patients completed an fMRI n-back working memory task both before and after the assigned treatment, and matched healthy controls were tested and compared to the untreated patients.
Results:
There were no whole-brain differences between any of the groups. However, when specified regions of interest were investigated, the patient group showed enhanced BOLD responses in dorsal and ventral areas before treatment. This increase was correlated with performance across all participants and with attention deficit/hyperactivity disorder symptoms in the patient group. Furthermore, we found an effect of treatment in the right superior frontal gyrus, with methylphenidate-treated patients exhibiting increased activation, which was absent in the placebo-treated patients.
Conclusions:
Our results indicate distinct activation differences between untreated adult attention deficit/hyperactivity disorder patients and matched healthy controls during a working memory task. These differences might reflect compensatory efforts by the patients, who are performing at the same level as the healthy controls. We furthermore found a positive effect of methylphenidate on the activation of a frontal region of interest. These observations contribute to a more thorough understanding of adult attention deficit/hyperactivity disorder and provide impulses for the evaluation of therapy-related changes.
1p36 deletion syndrome represents the most common terminal deletion observed in humans. Major clinical findings comprise developmental delay/intellectual disability, poor or absent expressive language, congenital central muscular hypotonia, brain anomalies, brachydactyly/camptodactyly, short feet, and characteristic facial features like straight eyebrows, deep-set eyes, and midface hypoplasia. So far, there is very limited knowledge about comorbid psychiatric disorders and their effective treatment in this special population. To fill this gap, this case report presents an initially four-year-old girl with 1p36.33–1p36.32 deletion, moderate intellectual disability, insomnia, oppositional-defiant disorder and attention deficit/hyperactivity disorder covering a period of time of about 1.5 years comprising initial psychological/psychiatric assessment, subsequent day clinic/outpatient treatment (amongst others including off-label use of melatonin and methylphenidate as well as parent-child interaction therapy) and follow-up assessment. Follow-up results indicated good efficacy of melatonin and methylphenidate medication without any adverse effects. Multidisciplinarity in diagnosis and treatment are mandatory to meet needs of patients with complex genetic disorders like 1p36 deletion syndrome. Off-label use of melatonin (for insomnia) and methylphenidate (for attention deficit/hyperactivity disorder) should be considered in young children with 1p36 deletion syndrome if behavioral interventions are not sufficient.
At present, there is a lack of longitudinal studies on the psychological adjustment of both children and adolescents with 22q11.2 deletion syndrome (22q11.2DS) and their primary caregivers. To fill this gap, we performed a four-year follow-up study. Mothers filled out the Child Behavior Checklist 4–18, the Social Orientation of Parents with Handicapped Children questionnaire to assess maternal stress and coping strategies, and the Freiburger Personality Inventory-Revised — subscales strain and life satisfaction. Fifty-five subjects with 22q11.2DS (26 males and 29 females; age: M = 10.79 years, SD = 3.56 years) and their biological mothers (age: M = 40.84 years, SD = 4.68 years) were included in this study. Significantly higher levels of behavior problems than in the general population and an increase in these problems, especially internalizing ones, over time could be found. In contrast, maternal stress did not change significantly over time, but mothers demonstrated increased levels of strain and reduced life satisfaction at T2. Thus, careful monitoring as well as early and adequate interventions, if indicated, should be offered to families with a child with 22q11.2DS, not only for somatic complaints but also for problems with psychological adjustment.